AJMC finds MA payments ineffective
- AJMC published a February 4 study showing a 2017 Medicare Advantage payment bump for full-benefit dual eligibles did not meaningfully cut hospital or nursing-home use. - Plans serving mostly full Medicaid enrollees saw mean risk scores rise 8.9%, but outcome changes were small, not clinically significant, and often failed sensitivity tests. - That matters because D-SNP enrollment has surged, and policymakers are betting more MA money can improve care for beneficiaries with the highest needs.
Medicare Advantage payments for some of the sickest, poorest beneficiaries went up in 2017. The idea was simple enough — if plans got paid more for full-benefit dual eligibles, they might coordinate care better and keep people out of hospitals and nursing homes. But the new AJMC study says that mostly did not happen. The extra money showed up in plan payments, yet the big utilization measures barely moved. ### Who are these patients? These are people enrolled in both Medicare and Medicaid — dual eligibles. The paper zeroes in on community-dwelling beneficiaries with full Medicaid benefits, which usually means higher medical and social needs than partial-benefit duals. This is the group policymakers worry about most because their care is expensive, fragmented, and split across two programs that often do not work together well. (ajmc.com) ### What changed in 2017? CMS changed Medicare Advantage risk adjustment so full Medicaid status counted differently from partial Medicaid status. That pushed up risk scores, and therefore capitated payments, for community-dwelling dual eligibles with full Medicaid benefits. The study compares plans and beneficiaries affected by that payment change with similar dual-eligible groups that were not. (ajmc.com) ### How big was the payment bump? Pretty real. In plans where more than half of members had full Medicaid, mean risk scores rose 8.9% from the 2014-2016 period to 2017-2022, relative to other plans. So this was not a rounding-error policy tweak. Plans got materially higher payment signals for serving this population. ### So what actually happened on the ground? Not much that looked durable or clinically meaningful. (ajmc.com) For beneficiaries age 65 and older, the paper picked up small declines in mortality, inpatient use, and nursing-home use, but those changes were not clinically significant and did not hold up consistently in sensitivity checks. For beneficiaries younger than 65, there were no significant changes. Among skilled nursing facility users, the study also did not find significant shifts in readmissions, long stays, or mortality. ### Why is that a big deal? Because the whole policy logic was that higher reimbursement would buy better outcomes. If more money alone does not reduce hospitalizations or nursing-home use for full-benefit dual eligibles, then payment adequacy may not be the main bottleneck. The harder problem may be integration — getting Medicare, Medicaid, long-term care, behavioral health, and social supports to work as one system instead of a stack of disconnected benefits. (ajmc.com) ### Does this mean Medicare Advantage never helps? No — but it suggests plan design matters more than just payment level. Other recent work points to better retention in fully integrated dual-eligible special needs plans, or FIDE-SNPs, than in looser MA arrangements. In a 2025 JAMA Health Forum study of 2.7 million dual-eligible beneficiaries, 8.1% of FIDE-SNP enrollees disenrolled within a year, versus 18.3% in coordination-only D-SNPs and more than 28% in standard MA and look-alike plans. That does not prove better outcomes by itself, but it does hint that tighter integration may matter more than a richer benchmark. (ajmc.com) ### What is the catch here? The study tracks high-level outcomes that policymakers care about most — hospital use, nursing-home use, mortality. But extra payment could still have funded things that are harder to see in those measures, like care navigation or supplemental benefits. The problem is that Medicare Advantage has been expanding those benefits for dual eligibles for years, and evidence on whether they translate into better real-world outcomes is still thin. (jamanetwork.com) ### Bottom line? Basically, this is a warning shot for Medicare policy. More money went in. Meaningful utilization changes did not come out. If Washington wants better results for full-benefit dual eligibles, the next lever probably is not just higher MA payments — it is tighter integration, cleaner benefit design, and making the extra services usable in real life. (ajmc.com) (jamanetwork.com)
